IDL Diagnostics publishes annual report 2025
The company changes its name from AroCell, updates its strategy with a focus on urology and receives its first commercial CLIA orders in China.
See the latest news and media coverage for IDL Diagnostics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Swedish in vitro diagnostics company for cancer and bacterial diseases
idldiagnostics.comLast updated
In short: IDL Diagnostics posted Q2 revenue growth, named a CEO, and advanced China and Concile partnerships
The company changes its name from AroCell, updates its strategy with a focus on urology and receives its first commercial CLIA orders in China.
Revenue increased 43.5% to SEK 14.6 million. Gustav Sten succeeded Anders Hultman as CEO on May 28.
The meeting approved financial reports, elected board members and authorized a share issue.
He discusses his priorities focusing on commercialization and growth.
IDL Diagnostics AB has published its financial results for the second quarter and the first half ended June 30, 2026. For the second quarter...
A summary for the IDL Diagnostics AB share. Signals range from Strong Buy, Buy, Neutral, Sell to Strong Sell. It also offers detailed technical analysis...
IDL Diagnostics AB is a in vitro diagnostics company, which engages in the monitoring of hematological malignancies, breast cancer, and other solid tumors. Its products...
IDL Diagnostics today announces that the Board of Directors has appointed Gustav Sten as the new Chief Executive Officer (CEO). Gustav Sten will assume the...
Track IDL Diagnostics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to IDL Diagnostics and other trending companies.